All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Up to 12 Doses of Radium-223 Proven Safe in Bone-Metastatic Prostate Cancer

January 27th 2016

Retreatment with radium-223 dichloride (Xofigo) after initial therapy and progression was determined to be safe in patients with bone-metastatic castration-resistant prostate cancer.

Michael J. Hennessy Associates Launches The Institute for Value-Based Medicine to Translate Evidence-Based Research into Value-Based Decisions

January 27th 2016

Michael J. Hennessy Associates, Inc., a full-service health care communications company offering education, research and medical media, introduces The Institute for Value-Based Medicine, a comprehensive online source of timely data, information and perspectives related to value-based medicine.

Less May Be More: Refining HER2-Positive Breast Cancer Care

January 26th 2016

Mothaffar Rimawi, MD, discusses key recent data with HER2-targeted agents and the need to identify patients for whom optimal care may mean de-escalating therapy.

Panitumumab Improves Survival in Chemorefractory mCRC

January 25th 2016

Adding panitumumab (Vectibix) to best supportive care reduced the risk of death by 30% for patients with RAS wild-type chemorefractory metastatic colorectal cancer.

Radium-223 Benefits Survival, Not Just for Palliative Care

January 25th 2016

Phillip J. Koo, MD, discusses the benefits of radium-223 and why he thinks it is time the use of the drug becomes more widespread for the treatment of mCRPC, and potentially other cancers.

FDA Expands Nivolumab's Frontline Melanoma Approval to Include BRAF-Mutant Patients

January 23rd 2016

The FDA has expanded the frontline melanoma indications for nivolumab as a single agent and in combination with ipilimumab to include patients with BRAF mutations.

FDA Approves Carfilzomib Combo for Relapsed Multiple Myeloma

January 21st 2016

The FDA has approved carfilzomib (Kyprolis) in combination with dexamethasone or with lenalidomide plus dexamethasone for patients with relapsed/refractory multiple myeloma following prior treatment with 1 to 3 lines of therapy

FDA Grants Venetoclax Combination Breakthrough Designation in CLL

January 21st 2016

Venetoclax has received an FDA breakthrough therapy designation for use in combination with rituximab to treat patients with relapsed/refractory chronic lymphocytic leukemia.

Tackling Challenging Patient Populations in DLBCL

January 21st 2016

Kathryn Kolibaba, MD, discusses the significance of the PYRAMID and other studies, and how she hopes the treatment paradigm for diffuse large b-cell lymphoma will evolve in the future.

Radiation/Immunotherapy Combos Slow to Gain Traction, But Have Potential in Prostate Cancer

January 20th 2016

Steven Finkelstein, MD, explains why radiation and immunotherapy may be an effective combination in prostate cancer.

FDA Approves Maintenance Ofatumumab in CLL

January 19th 2016

The FDA has approved ofatumumab (Arzerra) for the extended treatment of patients with recurrent or progressive chronic lymphocytic leukemia who are in complete or partial response following at least two lines of therapy.

Study Reveals New Potential Breast Cancer Drug Combinations

January 18th 2016

The largest analysis of breast cancer cell function to date suggests dozens of new uses for existing drugs, new targets for drug discovery, and new drug combinations.

FDA Grants Priority Review to Lenvatinib/Everolimus Combo for RCC

January 18th 2016

The FDA has granted a priority review designation to the combination of lenvatinib and everolimus as a treatment for patients with metastatic renal cell carcinoma following one prior VEGF-targeted therapy.

Novel Approaches Explored in HER2-Positive Gastric Cancer

January 18th 2016

Yelena Y. Janjigian, MD, discusses possible causes of the negative LOGiC trial results, HER2 as a driver in esophagogastric cancer, and what the future holds for lapatinib.

Expert Discusses Emerging Agents and the Future of Follicular Lymphoma

January 18th 2016

John P. Leonard, MD, discusses the potential for lenalidomide, idelalisib, and ibrutinib in follicular lymphoma, possible combination therapies, and challenges that remain in the treatment of the disease.

Lenvatinib/Everolimus Combo Submitted for Approval in Advanced RCC

January 15th 2016

Regulatory filings have been submitted in the United States and Europe for the combination of lenvatinib and everolimus as a treatment for patients with metastatic renal cell carcinoma following a VEGF-targeted therapy.

Expert Explains USPSTF Breast Cancer Screening Guidelines

January 15th 2016

Anees B. Chagpar, MD, shares her thoughts on the final US Preventive Services Task Force guidelines and how they change the focus of breast cancer screening.

Acclaimed Oncologist/Researcher Ravi Salgia Joins City of Hope as Chair of Medical Oncology

January 15th 2016

Thoracic specialist will guide expansion of clinical programs, integrate research into patient care.

Yale Clinician Meets With Vice President's Staff on Cancer “Moonshot”

January 15th 2016

Patricia M. LoRusso, D.O. was among a group of 15 top cancer researchers and physician-scientists who met in Washington with aides to Vice President Joe Biden on Jan. 8 to discuss his â€œmoonshotâ€ program to advance cancer treatment.

Federal Agency Too Weak to Regulate 340B Drug Discount Program

January 15th 2016

A fresh study of the much exploited 340B Drug Discount Program says that draft guideline revisions under consideration would likely not be successful because the Health Resource and Services Administration does not have the statutory authority to impose or to enforce them.